These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1387 related items for PubMed ID: 21225866

  • 1. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
    Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH.
    Cancer; 2011 Jul 01; 117(13):2970-85. PubMed ID: 21225866
    [Abstract] [Full Text] [Related]

  • 2. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
    Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, Chi CW, Chiou SH, Yang DM, Lee CH.
    J Pharmacol Exp Ther; 2012 May 01; 341(2):410-23. PubMed ID: 22328572
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells.
    Chang CJ, Chiang CH, Song WS, Tsai SK, Woung LC, Chang CH, Jeng SY, Tsai CY, Hsu CC, Lee HF, Huang CS, Yung MC, Liu JH, Lu KH.
    Childs Nerv Syst; 2012 Mar 01; 28(3):363-73. PubMed ID: 22249380
    [Abstract] [Full Text] [Related]

  • 4. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells.
    Chen YW, Chen KH, Huang PI, Chen YC, Chiou GY, Lo WL, Tseng LM, Hsu HS, Chang KW, Chiou SH.
    Mol Cancer Ther; 2010 Nov 01; 9(11):2879-92. PubMed ID: 21062915
    [Abstract] [Full Text] [Related]

  • 5. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H, Zeng F, Xu L, Liu X, Huang Y.
    Mol Med Rep; 2013 Nov 01; 8(5):1511-8. PubMed ID: 24008862
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics.
    Feng BH, Liu AG, Gu WG, Deng L, Cheng XG, Tong TJ, Zhang HZ.
    Oncol Rep; 2013 Aug 01; 30(2):815-23. PubMed ID: 23708735
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway.
    Yang J, Liao D, Chen C, Liu Y, Chuang TH, Xiang R, Markowitz D, Reisfeld RA, Luo Y.
    Stem Cells; 2013 Feb 01; 31(2):248-58. PubMed ID: 23169551
    [Abstract] [Full Text] [Related]

  • 11. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma.
    Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF.
    Clin Cancer Res; 2008 Jul 01; 14(13):4085-95. PubMed ID: 18593985
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro.
    Mihatsch J, Toulany M, Bareiss PM, Grimm S, Lengerke C, Kehlbach R, Rodemann HP.
    Radiother Oncol; 2011 Jun 01; 99(3):300-6. PubMed ID: 21704411
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.
    Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH.
    PLoS One; 2008 Jul 09; 3(7):e2637. PubMed ID: 18612434
    [Abstract] [Full Text] [Related]

  • 16. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
    Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, Iwasaki H, Emoto M.
    Stem Cells; 2011 Oct 09; 29(10):1485-95. PubMed ID: 21919130
    [Abstract] [Full Text] [Related]

  • 17. The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells.
    Malanga D, De Marco C, Guerriero I, Colelli F, Rinaldo N, Scrima M, Mirante T, De Vitis C, Zoppoli P, Ceccarelli M, Riccardi M, Ravo M, Weisz A, Federico A, Franco R, Rocco G, Mancini R, Rizzuto A, Gulletta E, Ciliberto G, Viglietto G.
    Oncotarget; 2015 Dec 15; 6(40):42667-86. PubMed ID: 26486080
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
    Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, Iwakami S, Moriyama M, Moriyama H, Koizumi F, Takahashi K.
    PLoS One; 2014 Dec 15; 9(1):e86459. PubMed ID: 24489728
    [Abstract] [Full Text] [Related]

  • 19. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
    Song WS, Yang YP, Huang CS, Lu KH, Liu WH, Wu WW, Lee YY, Lo WL, Lee SD, Chen YW, Huang PI, Chen MT.
    J Chin Med Assoc; 2016 Oct 15; 79(10):538-45. PubMed ID: 27530866
    [Abstract] [Full Text] [Related]

  • 20. Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression.
    Bhummaphan N, Petpiroon N, Prakhongcheep O, Sritularak B, Chanvorachote P.
    Phytomedicine; 2019 Sep 15; 62():152932. PubMed ID: 31100681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.